Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A CD68-expressing tissue-homing subset in peripheral CD8+ T cells predicts response to anti-PD-1 therapy in lung cancer.

Created on 28 Oct 2026

Authors

Ying Wang, Jing Huang, Zhengyi Sun, Yumei Pei, Jiancheng Xu

Published in

Frontiers in immunology. Volume 17. Pages 1995008. Epub Oct 13, 2026.

Abstract

T-cell function is regulated by immunometabolism, and lysosomes are signaling hubs. CD68 (LAMP4), traditionally regarded as a monocyte/macrophage marker, has been largely neglected in T cell biology. We aimed to assess the link between CD68 expression in T cells and anti-PD-1 response in lung cancer, and its potential as an early dynamic biomarker in peripheral blood CD8+ T cells.
We analyzed transcriptomic (GSE126044, GSE135222, GSE166449) and single-cell (GSE207422) data from anti-PD-1-treated lung cancer cohorts to identify lysosome related pathways and key genes, validated with peripheral blood CD8+ T cell data (GSE111414). Prospectively, we enrolled lung cancer patients receiving anti-PD-1 therapy, collecting peripheral blood at baseline and week 3. Flow cytometry measured CD68 in CD8+ T cells and subsets, assessing association with response, progression-free survival (PFS), and functional markers (granzyme B, perforin, Ki-67, CD69, IFN-γ, IL-1β).
Responders showed enrichment of lysosome pathways and upregulation of 8 lysosome related genes including CD68, positively correlated with monocyte and T cell infiltration. Single-cell data linked CD68 expression in T cell to favorable response. After one cycle, the proportion of CD8+CD68+ T cells was lower in non-responders (P<0.05), with AUC 0.803 (P=0.044) and cutoff 1.015%, stratifying PFS (P=0.0225). CD68 was highest in naïve T cells at baseline, but decreased across subsets after treatment in non-responders (all P<0.01). Functionally, compared with CD8+CD68- T cells, CD8+CD68+ T cells exhibited lower expression of granzyme B and perforin but higher expression of Ki-67, CD69, IFN-γ, and IL-1β (all P<0.001), suggesting a CD8+ T cell state characterized by lower cytotoxicity and enhanced proliferative and cytokine producing capacities, accompanied by a tissue residency associated phenotype.
CD8+CD68+ T cells exhibit lower cytotoxicity but greater proliferative and cytokine producing capacities, together with a tissue residency associated phenotype, suggesting a precursor-like state. Low CD68 expression in tumor-infiltrating T cells and the post-treatment reduction of CD68 expression in peripheral blood CD8+ T cells are associated with resistance to anti-PD-1 therapy in lung cancer. These findings suggest that CD8+CD68+ T cells may serve as a potential early dynamic immune biomarker for monitoring and assessing response to anti-PD-1 therapy in lung cancer.

PMID:
42947988
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement